Poniard Pharmaceuticals Inc.

Application No.: 5256/CHENP/2009 Published on Nov. 20, Assigned to Poniard Pharmaceuticals for Stabilized Picoplatin Oral Dosage Form (U.S. Inventors)
US Fed News Service, Including US State News; 12/4/2009; 401 words; ...all from U.S., have developed a stabilized picoplatin oral dosage form. The patent has been assigned to Poniard Pharmaceuticals Inc., Washington, U.S. According to an abstract posted by the Indian Patent Office, "The invention provides...

FORM 8-K: PONIARD PHARMACEUTICALS ANNOUNCES FINANCIAL STATEMENTS, EXHIBITS
US Fed News Service, Including US State News; 12/3/2009; 418 words; WASHINGTON, Dec. 1 -- Poniard Pharmaceuticals, Inc., San Francisco, files Form 8-K (current...of registrant as specified in its charter is Poniard Pharmaceuticals, Inc. State of Incorporation: Washington Other...

PONIARD PHARMACEUTICALS REPORTS DISPOSITION BY PRINCIPAL ACCOUNTING OFFICER JACKSON (California)
US Fed News Service, Including US State News; 12/1/2009; 305 words; WASHINGTON, Dec. 1 -- Poniard Pharmaceuticals Inc. (PARD), South San Francisco, Calif., has filed a Form 4 with the Securities and Exchange Commission noting the change in...

Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results.
Cancer Weekly; 12/1/2009; 1352 words; Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) announced updated clinical data from its...clinical cardiac-related events, as expected (see also Poniard Pharmaceuticals, Inc.). New data for both clinical trials were presented today...

Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint.
Cancer Weekly; 12/1/2009; 864 words; Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) announced that its...see also Poniard Pharmaceuticals, Inc.). "We are disappointed that the...Administration, Poniard Pharmaceuticals Inc. This article was prepared by Cancer...